Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports

Epidermal Growth Factor Receptor (EGFR) and B-Raf (BRAF) mutations are two of the most important drivers identified in non-small-cell lung cancer (NSCLC). This report highlights two cases of patients diagnosed with metastatic NSCLC bearing concurrent EGFR and BRAF mutations at baseline and treated w...

Full description

Bibliographic Details
Main Authors: Loc Carlo Bao, Alessia Padovan, Andrea Boscolo Bragadin, Lorenzo Calvetti, Valentina Guarneri, Laura Bonanno, Stefano Indraccolo
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
liquid biopsy
EGFR
NSCLC
BRAF
co-mutation
NGS
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1363069/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1363069/full

Similar Items